Compounds for binding to ERα/β and GPR30, methods of treating disease states and conditions mediated through these receptors and identification thereof
The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases which are mediated through one or more of these receptors include cancer (particularly breast, reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease, as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.
1. A compound according to the chemical structure I:
Where X is N—R;
R is H, an optionally substituted C 1 -C 6 alkyl group or an optionally substituted —C(O)—(C 1 -C 6 ) alkyl group;
R 1 , R 2 and R 5 are each independently selected from H, OH, halogen (F, Br, Cl or I), a C 1 -C 6 optionally substituted carboxylic acid group, an optionally substituted O—(C 1 -C 6 )alkyl, an optionally substituted C 1 -C 6 hydrocarbyl or an optionally substituted aryl group:
R 3 and R 4 together form a 5-membered optionally substituted heteroaryl or heterocyclic group;
R 6 and R 7 together form a 5-membered optionally substituted carbocyclic group;
R 6′ is absent, H, CH 3 or a CH 2 CH 3 group;
R 7′ is absent, H, CH 3 or a CH 2 CH 3 group;
R 7″ is absent;
R 8′ is absent H, CH 3 or CH 2 CH 3 ;
R 10 , R 11 , R 12 and R 13 are each independently H, OH, NO 2 , halogen (F, Br, Cl or I), a C 1 -C 6 optionally substituted carboxylic acid group, optionally substituted O—(C 1 -C 6 )alkyl, optionally substituted —C 1 -C 6 )hydrocarbyl, an optionally substituted —C(O)—(C 1 -C 6 ) alkyl, an optionally substituted —C(O)—O—(C 1 -C 6 ) alkyl, an optionally substituted O—C(O)—(C 1 -C 6 ) alkyl, or an optionally substituted —C(O)—N(C 1 -C 6 )dialkyl;
R 14 together with the carbon to which R 7 is attached forms a 6-membered optionally substituted heterocyclic ring; or a stereoisomer or pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 according to the chemical structure II:
Where R, R 1 , R 2 , R 3 , R 4 , R 5 , R 8′ , R 10 , R 11 , R 12 and R 13 are each the same as described in claim 1 , or a stereoisomer or pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 having the chemical structure:
4. A compound according to claim 1 wherein R 3 and R 4 form a five-membered heterocyclic ring having two heteroatoms.
5. A compound according to claim 1 wherein R is H or a C 1 -C 3 alkyl group.
6. A compound according to claim 1 wherein at least one substituent and as many as three R 1 , R 2 , R 5 , R 10 , R 11 , R 12 and R 13 substituents is a halogen group or an optionally substituted C 1 -C 6 hydrocarbyl group.
7. A compound according to claim 6 wherein said at least one substituent is a halogen group.
8. The compound according to claim 7 wherein said halogen is F or Br.
9. The compound according to claim 1 wherein R 1 , R 2 or R 5 is a halogen or a C 1 -C 6 hydrocarbyl group and R 11 or R 12 is a halogen, a C 1 -C 6 keto group, a carboxyl acid group, carboxamido group optionally substituted (with at least one C 1 -C 3 alkyl group, or an optionally substituted —C(O)O—(C 1 -C 6 alkyl) or —O—C(O)—(C 1 -C 6 alkyl) group.
10. The compound according to claim 9 wherein said halogen is F or Br.
11. A compound according to claim 3 which is
12. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
13. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
14. A pharmaceutical composition comprising an effective amount of a compound according to claim 3 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
15. A pharmaceutical composition comprising an effective amount of a compound according to claim 5 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
16. A pharmaceutical composition comprising an effective amount of a compound according to claim 6 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
17. A pharmaceutical composition comprising an effective amount of a compound according to claim 7 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
18. A pharmaceutical composition comprising an effective amount of a compound according to claim 8 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
19. A pharmaceutical composition comprising an effective amount of a compound according to claim 9 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
20. A pharmaceutical composition comprising an effective amount of a compound according to claim 10 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
21. A pharmaceutical composition comprising an effective amount of a compound according to claim 11 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.
22. A compound according to claim 3 which is
23. A pharmaceutical composition comprising an effective amount of a compound according to claim 22 , optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.